{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:08:13Z","timestamp":1792638493042,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T00:00:00Z","timestamp":1576022400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000835","name":"University of Bath","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000835","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Juvenile dermatomyositis is a heterogeneous disease with variable clinical outcomes. Here, we describe the recognised subtypes of idiopathic inflammatory myositis which occur in children, with particular reference to disease-associated autoantibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Large cohort studies have demonstrated that myositis autoantibodies are common in juvenile dermatomyositis and can be found in the majority of patients. They identify homogenous clinical subgroups and inform prognosis, particularly the risks of developing interstitial lung disease. Descriptions of immune-mediated necrotising myositis in juvenile patients have highlighted a rare but important clinical subset typically associated with severe muscle disease and treatment resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>It is increasingly apparent that autoantibodies can provide detailed information on prognosis and the likely disease associations in those with juvenile dermatomyositis. Further work is needed to establish how this knowledge should influence our approach to treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11926-019-0871-4","type":"journal-article","created":{"date-parts":[[2019,12,11]],"date-time":"2019-12-11T07:55:28Z","timestamp":1576050928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Juvenile Dermatomyositis\u2014Clinical Phenotypes"],"prefix":"10.1007","volume":"21","author":[{"given":"Danyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L","family":"Tansley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,11]]},"reference":[{"issue":"8","key":"871_CR1","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/rheumatology\/34.8.732","volume":"34","author":"DP Symmons","year":"1995","unstructured":"Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995;34(8):732\u20136.","journal-title":"Br J Rheumatol"},{"issue":"3","key":"871_CR2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/art.11122","volume":"49","author":"EP Mendez","year":"2003","unstructured":"Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995\u20131998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum. 2003;49(3):300\u20135.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"871_CR3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975a;292(7):344\u20137.","journal-title":"N Engl J Med"},{"issue":"8","key":"871_CR4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975b;292(8):403\u20137.","journal-title":"N Engl J Med"},{"issue":"12","key":"871_CR5","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955\u201364.","journal-title":"Ann Rheum Dis"},{"key":"871_CR6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","volume":"84","author":"Sarah L. Tansley","year":"2017","unstructured":"\u2022\u2022 Tansley SL, Simou S, Shaddick G, Betteridge ZE, Almeida B, Gunawardena H, et al. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J Autoimmun. 2017a;84:55\u201364. Description of the autoantibody associated disease phenotypes of a large UK JDM cohort using prospectively collected data","journal-title":"Journal of Autoimmunity"},{"issue":"4","key":"871_CR7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","volume":"92","author":"LG Rider","year":"2013","unstructured":"Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine. 2013;92(4):223\u201343.","journal-title":"Medicine."},{"key":"871_CR8","doi-asserted-by":"crossref","unstructured":"Iwata N, Nakaseko H, Kohagura T, Yasuoka R, Abe N, Kawabe S, et al. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: experience at a single center in Japan. Mod Rheumatol. 2018:1\u20136.","DOI":"10.1080\/14397595.2018.1511025"},{"issue":"11","key":"871_CR9","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.39753","volume":"68","author":"CT Deakin","year":"2016","unstructured":"Deakin CT, Yasin SA, Simou S, Arnold KA, Tansley SL, Betteridge ZE, et al. Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis. Arthritis Rheum. 2016;68(11):2806\u201316.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"871_CR10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/nan.12528","volume":"45","author":"SA Yasin","year":"2019","unstructured":"\u2022 Yasin SA, Schutz PW, Deakin CT, Sag E, Varsani H, Simou S, et al. Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features. Neuropathol Appl Neurobiol. 2019;45(5):495\u2013512 A description of the histopathological phenotypes found in a large cohort of JDM patients, including how these relate to autoantibody subgroup.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"12","key":"871_CR11","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","volume":"53","author":"SL Tansley","year":"2014","unstructured":"Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology. 2014a;53(12):2204\u20138.","journal-title":"Rheumatology."},{"issue":"11","key":"871_CR12","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.3899\/jrheum.090461","volume":"36","author":"G Espada","year":"2009","unstructured":"Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol. 2009;36(11):2547\u201351.","journal-title":"J Rheumatol"},{"issue":"5","key":"871_CR13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/rheumatology\/kex516","volume":"57","author":"J Aouizerate","year":"2018","unstructured":"Aouizerate J, De Antonio M, Bader-Meunier B, Barnerias C, Bodemer C, Isapof A, et al. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. Rheumatology. 2018;57(5):873\u20139.","journal-title":"Rheumatology."},{"issue":"6","key":"871_CR14","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/art.24547","volume":"60","author":"H Gunawardena","year":"2009","unstructured":"Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009;60(6):1807\u201314.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"871_CR15","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12969-018-0299-9","volume":"16","author":"AB Orandi","year":"2018","unstructured":"Orandi AB, Dharnidharka VR, Al-Hammadi N, Baszis KW. Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. Pediatric rheumatology online journal. 2018;16(1):84.","journal-title":"Pediatric rheumatology online journal"},{"issue":"2","key":"871_CR16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/MD.0b013e31816bc604","volume":"87","author":"A Bingham","year":"2008","unstructured":"Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, et al. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity. Medicine. 2008;87(2):70\u201386.","journal-title":"Medicine."},{"issue":"3","key":"871_CR17","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/kem359","volume":"47","author":"H Gunawardena","year":"2008","unstructured":"Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H, et al. Clinical associations of autoantibodies to a p155\/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology. 2008;47(3):324\u20138.","journal-title":"Rheumatology."},{"issue":"suppl_7","key":"871_CR18","first-page":"kex390.017","volume":"56","author":"B Almeida","year":"2017","unstructured":"Almeida B, Tansley S, Simou S, Gunawardena H, McHugh N, Wedderburn L. Anti-synthetase autoantibody is seen in patients with overlap myositis in the UK cohort of patients with Jveunile Dermatomyositis. Rheumatology. 2017;56(suppl_7):kex390.017.","journal-title":"Rheumatology"},{"issue":"4","key":"871_CR19","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","volume":"16","author":"SL Tansley","year":"2014","unstructured":"Tansley SL, Betteridge ZE, Gunawardena H, Jacques TS, Owens CM, Pilkington C, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Research & Therapy. 2014b;16(4):R138.","journal-title":"Arthritis Research & Therapy"},{"issue":"5","key":"871_CR20","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52(5):1571\u20136.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"871_CR21","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jpeds.2010.11.033","volume":"158","author":"I Kobayashi","year":"2011","unstructured":"Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr. 2011;158(4):675\u20137.","journal-title":"J Pediatr"},{"issue":"5","key":"871_CR22","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/rheumatology\/keu385","volume":"54","author":"N Kobayashi","year":"2015","unstructured":"Kobayashi N, Takezaki S, Kobayashi I, Iwata N, Mori M, Nagai K, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology. 2015;54(5):784\u201391.","journal-title":"Rheumatology."},{"key":"871_CR23","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, et al. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Annals of the rheumatic diseases. Epub ahead of print 2019. Analysis of the impact of anti-Ro52 on phenotype of US JDM patients. An association with ILD and poorer prognosis is described","DOI":"10.1136\/annrheumdis-2018-215004"},{"issue":"4","key":"871_CR24","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2005.10.041","volume":"54","author":"P Gerami","year":"2006","unstructured":"Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597\u2013613.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"871_CR25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archdermatol.2009.328","volume":"146","author":"MJ Bendewald","year":"2010","unstructured":"Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County. Minnesota Archives of dermatology. 2010;146(1):26\u201330.","journal-title":"Minnesota Archives of dermatology"},{"issue":"10","key":"871_CR26","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/ard.2008.097162","volume":"68","author":"ZE Betteridge","year":"2009","unstructured":"\u2022\u2022 Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis. 2009;68(10):1621\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"871_CR27","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","volume":"76","author":"F Bellutti Enders","year":"2017","unstructured":"Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"871_CR28","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","volume":"49","author":"K Hoshino","year":"2010","unstructured":"Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology. 2010;49(9):1726\u201333.","journal-title":"Rheumatology."},{"issue":"4","key":"871_CR29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060442","volume":"8","author":"Y Hamaguchi","year":"2013","unstructured":"Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One. 2013;8(4):e60442.","journal-title":"PLoS One"},{"issue":"4","key":"871_CR30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMc1506827","volume":"373","author":"MC Dalakas","year":"2015","unstructured":"Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015;373(4):393\u20134.","journal-title":"N Engl J Med"},{"issue":"1","key":"871_CR31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MD.0b013e31827f264d","volume":"92","author":"M Shah","year":"2013","unstructured":"Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine. 2013;92(1):25\u201341.","journal-title":"Medicine."},{"issue":"1","key":"871_CR32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12969-017-0205-x","volume":"15","author":"EL Binns","year":"2017","unstructured":"Binns EL, Moraitis E, Maillard S, Tansley S, McHugh N, Jacques TS, et al. Effective induction therapy for anti-SRP associated myositis in childhood: a small case series and review of the literature. Pediatric rheumatology Online Journal. 2017;15(1):77.","journal-title":"Pediatric rheumatology Online Journal"},{"key":"871_CR33","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","volume":"101","author":"Z Betteridge","year":"2019","unstructured":"Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019;101:48\u201355.","journal-title":"J Autoimmun"},{"issue":"2","key":"871_CR34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/acr.22920","volume":"69","author":"I Pinal-Fernandez","year":"2017","unstructured":"Pinal-Fernandez I, Parks C, Werner JL, Albayda J, Paik J, Danoff SK, et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res. 2017a;69(2):263\u201370.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"871_CR35","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.160871","volume":"44","author":"SL Tansley","year":"2017","unstructured":"\u2022 Tansley SL, Betteridge ZE, Simou S, Jacques TS, Pilkington C, Wood M, et al. Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients. J Rheumatol. 2017b;44(4):488\u201392 A description of 4 JDM patients with anti-HMGCR and a description of the associated phenotype. Although rare, this autoantibody is associated with severe and treatment resistant disease.","journal-title":"J Rheumatol"},{"issue":"7","key":"871_CR36","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/acr.23113","volume":"69","author":"Takayuki Kishi","year":"2017","unstructured":"\u2022 Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, et al. Association of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies with DRB1*07:01 and severe myositis in juvenile myositis patients. Arthritis Care Res. 2017;69(7):1088\u201394. A large study of JDM patients which demonstrates anti-HMGCR to be associated with more severe disease. HLA association is also reported.","journal-title":"Arthritis Care & Research"},{"issue":"3","key":"871_CR37","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","volume":"63","author":"AL Mammen","year":"2011","unstructured":"Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713\u201321.","journal-title":"Arthritis Rheum"},{"issue":"4\u20135","key":"871_CR38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.autrev.2014.01.022","volume":"13","author":"M Mahler","year":"2014","unstructured":"Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev. 2014;13(4\u20135):367\u201371.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"871_CR39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","volume":"73","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73(1):227\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"871_CR40","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/rheumatology\/kep455","volume":"49","author":"B Hervier","year":"2010","unstructured":"Hervier B, Wallaert B, Hachulla E, Adoue D, Lauque D, Audrain M, et al. Clinical manifestations of anti-synthetase syndrome positive for anti-alanyl-tRNA synthetase (anti-PL12) antibodies: a retrospective study of 17 cases. Rheumatology. 2010;49(5):972\u20136.","journal-title":"Rheumatology."},{"issue":"6","key":"871_CR41","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.21883","volume":"54","author":"Y Yamasaki","year":"2006","unstructured":"Yamasaki Y, Yamada H, Nozaki T, Akaogi J, Nichols C, Lyons R, et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis\/dermatomyositis. Arthritis Rheum. 2006;54(6):2004\u20139.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"871_CR42","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s10067-016-3258-1","volume":"35","author":"M Giannini","year":"2016","unstructured":"Giannini M, Notarnicola A, Dastmalchi M, Lundberg IE, Lopalco G, Iannone F. Heterogeneous clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case series. Clin Rheumatol. 2016;35(9):2363\u20137.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"871_CR43","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/art.22506","volume":"56","author":"M Hirakata","year":"2007","unstructured":"Hirakata M, Suwa A, Takada T, Sato S, Nagai S, Genth E, et al. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum. 2007;56(4):1295\u2013303.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"871_CR44","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/rheumatology\/kel435","volume":"46","author":"S Sato","year":"2007","unstructured":"Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti-OJ (anti-isoleucyl-tRNA synthetase) autoantibodies. Rheumatology. 2007;46(5):842\u20135.","journal-title":"Rheumatology."},{"issue":"6","key":"871_CR45","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","volume":"56","author":"I Pinal-Fernandez","year":"2017","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C, et al. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology. 2017b;56(6):999\u20131007.","journal-title":"Rheumatology."}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-019-0871-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-019-0871-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-019-0871-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T01:40:47Z","timestamp":1665193247000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-019-0871-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["871"],"URL":"https:\/\/doi.org\/10.1007\/s11926-019-0871-4","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"11 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No potential conflicts of interest relevant to this article were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"74"}}